Prestige Consumer Healthcare (NYSE:PBH) Price Target Raised to $93.00

Prestige Consumer Healthcare (NYSE:PBH) had its price objective increased by Oppenheimer from $87.00 to $93.00 in a research note released on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

Several other equities research analysts have also recently weighed in on the company. DA Davidson upped their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Sidoti downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a report on Monday, December 9th. StockNews.com upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 24th. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Finally, Canaccord Genuity Group upped their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $92.60.

Prestige Consumer Healthcare Trading Down 0.1 %

Shares of PBH stock opened at $85.62 on Thursday. The company has a current ratio of 3.68, a quick ratio of 2.10 and a debt-to-equity ratio of 0.56. The stock has a market cap of $4.23 billion, a P/E ratio of 20.05, a price-to-earnings-growth ratio of 2.43 and a beta of 0.50. The stock has a 50 day simple moving average of $79.30 and a 200 day simple moving average of $76.01. Prestige Consumer Healthcare has a 1 year low of $62.35 and a 1 year high of $88.36.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. On average, research analysts predict that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Insider Activity at Prestige Consumer Healthcare

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the sale, the chief executive officer now directly owns 320,952 shares in the company, valued at $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.60% of the stock is currently owned by company insiders.

Institutional Trading of Prestige Consumer Healthcare

A number of large investors have recently bought and sold shares of the business. Martingale Asset Management L P boosted its position in shares of Prestige Consumer Healthcare by 0.4% during the 3rd quarter. Martingale Asset Management L P now owns 36,971 shares of the company’s stock worth $2,666,000 after purchasing an additional 140 shares in the last quarter. Horizon Kinetics Asset Management LLC lifted its position in Prestige Consumer Healthcare by 4.8% in the 3rd quarter. Horizon Kinetics Asset Management LLC now owns 3,247 shares of the company’s stock valued at $234,000 after acquiring an additional 150 shares in the last quarter. Franklin Resources Inc. lifted its position in Prestige Consumer Healthcare by 0.7% in the 4th quarter. Franklin Resources Inc. now owns 21,735 shares of the company’s stock valued at $1,697,000 after acquiring an additional 150 shares in the last quarter. CIBC Private Wealth Group LLC lifted its position in Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock valued at $34,000 after acquiring an additional 152 shares in the last quarter. Finally, OLD National Bancorp IN lifted its position in Prestige Consumer Healthcare by 4.4% in the 3rd quarter. OLD National Bancorp IN now owns 3,974 shares of the company’s stock valued at $287,000 after acquiring an additional 168 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.